145484-45-3 Usage
Uses
Used in Pharmaceutical Industry:
1-Pyrrolidineaceticacid,3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-alpha-(2-methylpropyl)-2-oxo-,[S-(R,S)]-(9CI) is used as a dipeptide peptidomimetic for the development of pharmaceutical compounds targeting the Gly-Val sequence. Its unique structure allows for the creation of novel drugs with potential applications in various therapeutic areas.
Used in Chemical Synthesis:
In the field of chemical synthesis, 1-Pyrrolidineaceticacid,3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-alpha-(2-methylpropyl)-2-oxo-,[S-(R,S)]-(9CI) serves as a key intermediate in the synthesis of Fmoc-Freidinger's lactam. This lactam is crucial for the development of various peptides and peptidomimetics, which have a wide range of applications in the pharmaceutical, biotechnological, and materials science industries.
Used in Research and Development:
Due to its unique structure and properties, 1-Pyrrolidineaceticacid,3-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-alpha-(2-methylpropyl)-2-oxo-,[S-(R,S)]-(9CI) is also utilized in research and development for the exploration of new peptide-based therapeutics and the study of peptide-protein interactions. Its potential applications in this field could lead to the discovery of new drugs and治疗方法 (治疗方法) for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 145484-45-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,5,4,8 and 4 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 145484-45:
(8*1)+(7*4)+(6*5)+(5*4)+(4*8)+(3*4)+(2*4)+(1*5)=143
143 % 10 = 3
So 145484-45-3 is a valid CAS Registry Number.
145484-45-3Relevant articles and documents
Cyclic peptides as selective tachykinin antagonists
Williams,Curtis,McKnight,Maguire,Young,Veber,Baker
, p. 2 - 10 (2007/10/02)
Twenty homodetic cyclic peptides based on the C-terminal sequence of substance P were prepared (Table I) by a combination of solid-phase techniques and cyclizations using azide coupling procedures. Incorporation of dipeptide mimics based on substituted γ-